Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.44 |
| ▸ | CA1 | P00915 | 6/20 | 0.44 |
| ▸ | CA2 | P00918 | 6/20 | 0.44 |
| ▸ | CA9 | Q16790 | 6/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4421353 | 1.00 | — | — | |
| SCHEMBL1640600 | 0.86 | — | — | |
| SCHEMBL1126889 | 0.86 | — | — | |
| SCHEMBL13158245 | 0.85 | CA12 (0.35) | CA12CA1CA2CA9 | |
| SCHEMBL14533199 | 0.85 | CA12 (0.35) | CA12CA1CA2CA9 | |
| SCHEMBL501982 | 0.85 | MGLL (0.54) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL8112681 | 0.83 | CA1 (0.52) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL16155543 | 0.83 | CA1 (0.52) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL1259911 | 0.83 | — | — | |
| SCHEMBL1458895 | 0.83 | CA12 (0.33) | CA12CA1CA2CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060223789-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | NABRIVA THERAPEUTICS AG (AT) | 2006-10-05 | — | — | US | disclosed |
| US-20040132709-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | ASCHER GERD (AT) | 2004-07-08 | — | — | US | disclosed |
| US-6693095-B2 | 7-(((5-AMINO-1,2,4-THIADIAZOL-3-YL)-(Z)-(FLUORMETHOXYIMINO) -ACETYL)AMINO)-3(E)-((IMINO-1-PIPERAZINYLMETHYL)-METHYLHYDRAZONO)METHYL-3 -CEPHEM-4-CARBOXYLIC ACID TRIHYDROCHLORIDE FOR EXAMPLE | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 2004-02-17 | — | — | US | disclosed |
| US-20030114665-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | ASCHER GERD (AT) | 2003-06-19 | — | — | US | disclosed |
| EP-1300408-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono)methyl-cephalosporins and intermediates | BIOCHEMIE Gesellschaft m.b.H. (AT) | 2003-04-09 | — | — | EP | disclosed |
| US-20020115852-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | ASCHER GERD (AT) | 2002-08-22 | — | — | US | disclosed |
| US-20020091252-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | NABRIVA THERAPEUTICS AG (AT) | 2002-07-11 | — | — | US | disclosed |
| EP-0973780-A1 | ANTIBACTERIAL SUBSTITUTED 7-ACYLAMINO -3-(METHYLHYDRAZONO) METHYL-CEPHALOSPORINS AND INTERMEDIATES | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 2000-01-26 | — | — | EP | disclosed |
| WO-1998043981-A1 | ANTIBACTERIAL SUBSTITUTED 7-ACYLAMINO-3-(METHYLHYDRAZONO)METHYL -CEPHALOSPORINS AND INTERMEDIATES | BIOCHEMIE GESELLSCHAFT MBH (AT) | 1998-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114665-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | MRPL21, Q6ZSR9, EMG1 | CA12 4665/4885CA1 4759/4885CA2 4134/4885 |
| US-20020115852-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | MRPL21, Q6ZSR9, EMG1 | CA12 4665/4885CA1 4759/4885CA2 4134/4885 |
| US-20020091252-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | MRPL21, Q6ZSR9, EMG1 | CA12 4665/4885CA1 4759/4885CA2 4134/4885 |
| US-20060223789-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | MRPL21, Q6ZSR9, PRMT7 | CA12 4718/4885CA1 4858/4885CA2 4341/4885 |
| US-20040132709-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | MRPL21, Q6ZSR9, EMG1 | CA12 4665/4885CA1 4759/4885CA2 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.